2.3. Resultados y discusión
2.3.2. Hábitos de consumo de medicamentos y productos de uso personal
2001;409(6823):1055-1060. G eneral introduction
P
T
E
R
1
93. 94. 95. 96. 97. 98. 99. 100. 1 0 1 . 10 2 . 103. 104. 105. 106. 107.
Pende D, Parolini S, Pessino A et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med. 1999;190(10):1505-1516.
Bottino C, Biassoni R, Millo R, Moretta L, Moretta A. The human natural
cytotoxicity receptors (NCR) that induce HLA class I-independent NK cell triggering. Hum Immunol. 2000;61(1):1-6.
Arnon TI, Achdout H, Levi O et al. Inhibition of the NKp30 activating receptor by p65 of human cytomegalovirus. Nat Immunol. 2005;6(5):515-523.
Bottino C, Castriconi R, Moretta L, Moretta A. Cellular ligands of activating NK receptors. Trends Immunol. 2005;26(4):221-226.
Fauriat C, Moretta A, Olive D, Costello RT. Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. Blood. 2005;106(6):2186-2188.
Fauriat C, Just-Landi S, Mallet F et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemic cells in NCRdul' phenotype induction. Blood. 2007;109(1):323-330.
Cantoni C, Bottino C, Vitale M et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the
immunoglobulin superfamily. J Exp Med. 1999;189(5):787-796.
Wu J, Song Y, Bakker AB et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999;285(5428):730-732.
Cosman D, Mullberg J, Sutherland CL et al. ULBPs, novel MHC class I-related molecules, bind to CM V glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14(2):123-133.
Farrell H, gli-Esposti M, Densley E et al. Cytomegalovirus MHC class I homologues and natural killer cells: an overview. Microbes Infect. 2000;2(5):521-532.
Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000;1(2):119-126.
Sutherland CL, Rabinovich B, Chalupny NJ et al. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood. 2006;108(4):1313-1319.
Pende D, Cantoni C, Rivera P et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol. 2001;31(4):1076-1086. Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J Exp Med. 2000;192(7):1059-1068.
Das H, Groh V, Kuijl C et al. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity. 2001;15(1):83-93.
109. 110 . 1 1 1 . 1 1 2 . 113. 114. 115. 116. 117. 118. 119. 12 0 . 1 2 1 . 12 2 . 108. 123.
Groh V, Rhinehart R, Randolph-Habecker J et al. Costimulation of CD8aß T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol. 2001;2(3):255-260.
Ugolini S, Vivier E. Multifaceted roles of MHC class I and MHC class I-like molecules in T cell activation. Nat Immunol. 2001;2(3):198-200.
Biassoni R, Cantoni C, Pende D et al. Human natural killer cell receptors and co-receptors. Immunol Rev. 2001;181:203-214.
Vitale M, Falco M, Castriconi R et al. Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol. 2001;31(1):233-242. Sivori S, Parolini S, Falco M et al. 2B4 functions as a co-receptor in human NK cell activation. Eur J Immunol. 2000;30(3):787-793.
Lanier LL, Ruitenberg JJ, Phillips JH. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol. 1988;141(10):3478-3485. Moretta A, Poggi A, Pende D et al. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta. J Exp Med. 1991;174(6):1393-1398.
Shibuya A, Campbell D, Hannum C et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4(6):573-581. Snell GD. Recognition structures determined by the H-2 complex. Transplant Proc. 1976;8(2):147-156.
Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-
deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319(6055):675-678.
Ljunggren HG, Sturmhofel K, Wolpert E, Hammerling GJ, Karre K. Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants. J Immunol. 1990;145(1):380-386.
Franksson L, George E, Powis S et al. Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene. J Exp Med. 1993;177(1):201-205.
Ljunggren HG, Karre K. In search of the 'missing self: MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237-244.
Valiante NM, Uhrberg M, Shilling HG et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7(6):739-751.
Salcedo M, Diehl AD, Olsson-Alheim MY et al. Altered expression of Ly49
inhibitory receptors on natural killer cells from MHC class I-deficient mice. J Immunol. 1997;158(7):3174-3180.
Sentman CL, Olsson MY, Karre K. Missing self recognition by natural killer cells in MHC class I transgenic mice. A 'receptor calibration' model for how effector cells
G eneral introduction
P
T
E
R
1
124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136.
adapt to self. Semin Immunol. 1995;7(2):109-119.
Kim S, Poursine-Laurent J, Truscott SM et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436(7051):709-713. Cooley S, Xiao F, Pitt M et al. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self MHC is develop mentally immature. Blood. 2007;110(2):578-586.
Fernandez NC, Treiner E, Vance RE et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood. 2005;105(11):4416-4423.
Pawelec G, Da SP, Max H et al. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. Leuk Lymphoma. 1995;18(5-6):471-478.
Pierson BA, Miller JS. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood. 1996;88(6):2279-2287.
Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood. 1996;87(6):2476-2485.
Cook MA, Milligan DW, Fegan CD et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood. 2004;103(4):1521-1526.
Giebel S, Nowak I, Wojnar J et al. Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation. Transplant Proc. 2006;38(1):287-291.
Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562): 2097-2100.
van der Meer A, Schaap NPM, Schattenberg AVMB et al. KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients. Molecular Immunology. 2008;45(13):3631-3638.
Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell
alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94(1):333-339.
Kim DH, Won DI, Lee NY et al. Non-CD34(+) cells, especially CD8(+) cytotoxic T cells and CD56(+) natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(7):719-728.
137. 138. 139. 140. 141. 142.
outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007;21(10):2145-2152.
Ruggeri L, Mancusi A, Capanni M et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic trans plantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110(1):433-440.
Olson JA, Leveson-Gower DB, Gill S et al. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010:115(21):4293-4301.
Koehl U, Sorensen J, Esser R et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004;33(3):261-266.
Passweg JR, Tichelli A, Meyer-Monard S et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004;18(11):1835-1838.
Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-3057.
Shi J, Tricot G, Szmania S et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008;143(5):641-653.
G eneral introduction